Proliferating cells require iron and, therefore, express the transferrin receptor (CD71) that mediates cellular iron uptake. Cycling thymocytes, which have the CD4-8-3-, CD4-8+3-, or CD4+8+3-phenotypes, also express CD71. The importance of CD71-mediated iron uptake for proliferation and maturation of thymocytes was studied using fetal thymus organ cultures at day 14 of gestation and treating them for 7 days with a CD71 monoclonal antibody (mAb). The intracellular iron deficiency caused by this treatment, inhibits both proliferation and maturation of the thymocytes. Cell recovery was reduced by 60 % , but cells still expanded tenfold during the culture. Remarkably, the final maturation of ap T cells was completely blocked as no thymocytes with low or high CD3/a(3TcR expression developed. Moreover, only few cells reached the CD4+8+3-stage of T cell development. CD4-8-3-thymocytes, however, as well as its CD44-25+ subset developed in normal numbers, suggesting that CD44-25+ CD4-8-3-cells, or their immediate progeny, were most vulnerable to CD71 mAb treatment. The development of y6 T cells,which also express CD71,was not affected in these cultures. This suggests that y6 T cells are either less iron-dependent or possess alternative iron-uptake mechanisms. Thus, our observations indicate that CD71 treatment, causing decreased intracellular iron levels, severely inhibits the major proliferation phase from the CD44-25+ CD4-8-3-to the CD4+8+3-cells, and completely abrogates the final maturation of CD4+8+3-cells into a@TcR-expressing cells. In contrast, proliferation and differentiation of the earliest thymic precursors into CD44-25+ CD4-8-3-cells is not affected by CD71 treatment.
Introduction
The thymus provides a unique environment for the development of T lymphocytes, supporting both precursor cell proliferation and maturation [l] .These precursor cells, with a CD4-8-3-phenotype, differentiate in the thymus via CD4-8+3-, CD4+8+3-and CD4+8+3'oWcells into mature CD4+8-and CD4-8+ thymocytes, expressing the CD3/apTcR complex at the cell surface [2-61. In addition, the CD4-8-3-cells are heterogenous and can be divided into three subpopulations on the basis of expression of Pgp-1 (CD44) and the p55-chain of the interleukin-2 receptor (IL-2Ra or CD25): CD44+25-cells develop via CD44-25+ into CD44-25-cells . Within this scheme of T cell development, a major expansion phase starts at the CD44-25+ CD4-8-3-stage of T cell development. This [I 121711 phase of intense proliferation ends within the CD4+8+3-thymocyte subpopulation, indicating that cell division ceases before the CDYapTcR complex is expressed on the surface of the CD4+8+ thymocyte [3, 10, 111 .
Recently, we observed that this major expansion phase in early T cell development is marked by the expression of the transferrin receptor (CD71; [12] ). Thymocytes with CD4-8-3-, CD4-8+3-and CD4+8+3-phenotypes in both fetal and adult thymus expressed CD71 [12] .These subpopulations also contain almost all cycling cells present within the thymus [3, 5, 8, 10, 131 , and through DNA analysis we found that CD71 expression on thymocytes is closely related to proliferation [12] .
The transferrin receptor is involved with the uptake of iron delivered to the cell by the iron-transporting molecule, transferrin [14] . The internalized iron is either stored in ferritin deposits or used as a substrate for the biosynthesis of iron-containing proteins. Iron uptake by the proliferating cell is essential for the iron-containing enzyme ribonucleotide reductase involved with DNA synthesis 1151.
However, CD71 is not only expressed by cycling cells, but also by cells that require iron for other iron-dependent proteins, such as the enzyme peroxidase in monocytes. Similarly, the expression of CD71 by thymocytes is probably not only related to cell division, but may also reflect the use of iron by iron-containing proteins involved with maturation of the thymocytes. Therefore, we analyzed the role of the transferrin receptor-mediated iron uptake in T cell development. By treating fetal thymus organ cultures with the CD71 mAb ER-MP21[16] ,we observed that T cell proliferation was severely inhibited. Furthermore, we found that crp T cell development was completely abrogated, whereas development of y6 T cells was not affected by the treatment. The data presented here indicate that CD71 treatment has a major effect on the CD4-8-3-t hymocytes.
Materials and methods

Mice
Antibody blocking
Day 14 FTOC were treated with purified anti-transferrin receptor mAb ER-MP21 [16] , in concentrations of 25, 50 and 100 pg/ml. Subsequent cultures were treated with the high dose of 100 pg/ml ER-MP21 only. Control cultures received PBS only, or the IgG2a isotype control antibody ER-MP20 [23] at a dose of 100 pg/ml. All cultures received the same amount of PBS and the contribution of PBS to the cultures never exceeded 10 % . In FTOC day 14 + 12, mAb containing culture medium was replenished at day 6.
Fetal (gestational day 14) and adult BALB/c (H-2d) mice were bred and maintained in the animal facilities of our 2.5 Immunofluorescence and flow cytometric analysis department.
Antibodies
Viable thymocyte suspensions were prepared by disrupting four to five lobes in a small volume of PBS containing 0.5 % BSA and 2 mM sodium azide in a small potter homogenizer. Cells were washed. counted and subseauentlv used for analytical flow cytometry. Routinely, 1051 cells kere incubated with FITC-, biotin-, or R-phycoerythrin-conjugated mAb or an mAb mixture, followed by R-phycoerythrin or tricolor-conjugated streptavidin (Caltag, San Francisco, CA), as previously described [ 121. For double staining using hybridoma supernatant and CD4-R-phycoerythrin, cells were successively incubated with supernatant, FITCconiugated anti-rat antiserum, 3 % normal rat serum, and
The antibodies used in this study are listed in Table 1 [16-231. They were purified from hybridoma culture supernatant by affinity chromatography and conjugated with FITC or biotin. The CD4-R-phycoerythrin was commercially obtained (Becton Dickinson, Mountainview, CA) .To avoid aspecific staining, all conjugates were optimally titrated. R-phycoerythrin (PE).
Fetal thymus organ culture
Fetal thymus lobes were placed in organ culture, as described by Mandel [24] and Jenkinson [25] . Briefly, four to five single thymus lobes were placed on the surface of polycarbonate filters (0. 
CD71 expression in fetal thymus organ culture
Recently, we showed that in vivo CD71 was expressed by large, cycling thymocytes with CD4-8-3-, CD4-8+3-, and CD4+8+3-phenotypes, during both fetal and adult T cell development [12] . In the present study we determined the functional relevance of transferrin receptor-mediated iron uptake for proliferation and maturation of cells in this early phase of T cell development. To that purpose, fetal thymuses of gestational day 14 were cultured in the presence of the CD71 mAb ER-MP21. Using other target cells, such treatment resulted in growth inhibition of cells caused by iron starvation [16, 26] . We used FTOC, because (i) this system supports normal development of ap and y6 T cells [27] , and (ii) at the start of the culture, all day 14 fetal thymocytes were CD71-expressing CD4-8-cells [12] . However, first we established whether in vitro, i.e. during 7days of normal FTOC, CD71 was expressed by large immature thymocytes and was down-regulated when the aPTcR became expressed, as we observed in vivo [12] . We determined CD71 expression by thymocyte subpopulations after triple staining the cells with CD71, CD4 and either CD8 (Fig. 1 ) or the apTcR (data not shown). After 7 days of culture, we found that CD4-8-thymocytes developed into CD4+8+, CD4+8-and CD4-8+ cells (Fig. 1A) . At the same time, CD71 was down-regulated on developing small cells (Fig. 1B) . Subpopulation analysis showed that most CD4-8-thymocytes were large, CD71+ cells (Fig. 1C) . CD4+8+ thymocytes contained a major population of small CD71-cells and a minor population of large CD71+ cells (Fig. 1D) . The latter population did not express the aPTcR, whereas a subset of small CD4+8+ cells already did (data not shown). The CD4-8+ thymocytes were all large CD71+ cells (Fig. 1E ). These cells represent the immature CD4-8+3-cells, as mature apTcRhigh CD4-8+ cells had not yet developed under the in vitro conditions (data not shown; [ 121). The CD4+8-population, roughly selected using quadrant analysis (see Fig. lA ), contained both immature aPTcR-and mature aPTcR+ cells (data not shown). The aPTcR+ subset within the CD4+8-population does not express CD71 and has small to intermediate cell size (Fig. 1F ). Most cells of the y6 T cell lineage, identified as CD4-y6TcR+ cells, expressed CD71 and were large in cell size (Fig. lG,H) .
Our data indicate that in FTOC CD71 is expressed on immature CD4-8-, CD4-8+3-, and CD4+8+3-blast cells, including y6 T cells, as observed in vivo in fetal and adult T cell development [12].
Proliferation of thymocytes is inhibited by CD71 mAb treatment
Day 14 fetal thymuses were cultured in the presence of different doses of purified ER-MP21. We observed that cell recovery in such cultures was significantly reduced, as = 200,000 thymocytes per thymus lobe were recovered, i.e. only half the amount recovered from control cultures ( Table 2 ). This reduction of 50 % in cell recovery seemed independent of the mAb concentration in the range studied. Despite the CD71 treatment, cells still proliferated and expanded at least tenfold from the start of the organ culture, as day 14 fetal thymus contains only about 20,000 cells. Thus, CD71 treatment causes an inhibition, but not a complete abrogation of cell proliferation in the organ cultures. The optimal dose of the ER-MP21 mAb for functional studies was determined by establishing the dose of ER-MP21 mAb that results in complete saturation of CD71 molecules on the surface of the thymocytes in CD71 mAb-treated FTOC. The ER-MP21 mAb bound to the surface of the thymocyte during treatment was detected with a FITC-conjugated anti-rat antiserum using flow cytometry. We found that complete saturation was only obtained with the high dose of 100 yglml (data not shown). Therefore, the dose of 100 pg/ml was used in the remainder of this study.
Differentiation of apTcR+, but not yGTcR+ thymocytes is inhibited by CD71 mAb treatment
In addition to an effect on T cell proliferation, we also anticipated an effect of CD71 treatment on T cell differentiation, because CD71 is expressed by three immature thymocyte subpopulations, linked to each other by a proliferation-driven differentiation process. In CD71 mAb-So far, these data indicate that, af~ T cell differentiation is severely impaired by CD71 mAb treatment. Indeed, CD4+8-apTcRhigh and CD4+8+ ~~T C R '~" thymocytes, identified as CD4+3high and CD4+3'OW cells, respectively were completely absent in the CD71 mAb-treated cultures (Fig. 3A, B) . Remaining CD4+8+ thymocytes were TcR-. In contrast, there was a relative increase in the number of CD4-3+ thymocytes. As Fig. 3C and D indicate, these cells are all y6 T cells. Such a relative increase in the number of y6TcR+ thymocytes was observed in three different experiments (Table 3 ). Yet, in absolute numbers, the y6TcR+ population was similar in size in both CD71 mAb-treated and control cultures (Table 3) . treated cultures, cells were all large in size, whereas control cultures contained both small and large cells (Fig. 2A,  upper panels) . When thymocytes were stained simultaneously with CD4 and CD8 mAb, a dramatic inhibition of T cell differentiation was observed ( Fig. 2A, Zowerpanels) . CD4+8+ and CD4+8-thymocytes developed in very low numbers, causing a substantial (relative) increase in the number of CD4-8-thymocytes as compared to the control culture. In absolute numbers, CD4+8+ and CD4+8-cells were drastically reduced (Fig. 2B) . The reduction of the CD4+8+ thymocytes was not only caused by the almost complete absence of small CD4+8+ cells, but also by a reduction in the number of large CD4+8+ cells (data not shown). The number of CD4-8+ cells, however, was only mildly reduced, whereas more CD4-8-cells were recovered from CD71-treated cultures compared to control cultures. IL-2R+ cells, representing mainly the CD25+ CD4-8-3-thymocytes, were also recovered in slightly increased numbers (data not shown). a) The relative number of ysTcR+ thymocytes was determined from histograms; the absolute recovery was calculated using the relative number and total cell recovery of the organ cultures.
Together these results indicate that (i) T cell differentiation in the ap T cell lineage is completely abrogated by CD71 mAb treatment, (ii) thymocytes of the y6 T cell lineage are not affected, and (iii) within the CD4-8-compartment, cells seem to develop in normal numbers, at least up to the CD25+ stage. 
Inhibition of differentiation occurs independently of inhibition of proliferation
The question arises whether the observed inhibition of differentiation is a mere consequence of the inhibition of proliferation, or whether differentiation itself also requires iron uptake by the cells. When inhibition of differentiation is a mere consequence of the inhibition of proliferation, it may be expected that a CD71 mAb-treated culture and a control culture with identical cell number would have the same developmental stage. To test this assumption, we performed two experiments. In the first experiment, we analyzed the cell recovery and the developmental stage of the organ cultures through a period from day 3 to day 7 of the culture (Fig. 4A) . We found that cell number in the CD71 mAb-treated cultures increased more slowly with culture time, as compared with the control cultures.
Comparison of the cell recovery shows that the control In A , the cell recoveries at days 3 to 7 of the organ culture are shown for control and CD71 mAb treated cultures (indicated by bars with different bar patterns). Asterisks indicate the samples (of equal cell recovery) that were used for two-color staining with CD4 and CD8 mAb, presented in B. Cells from the control FTOC at day 4 and from the CD71 mAb-treated FTOC at day 7 were stained with CD4-biotin and CDS-FITC, followed by streptavidin-R-phycoerythrin. Subpopulations were quantified by quadrant analysis; the absolute numbers of cells ( X are indicated in the quadrants. In a second experiment, a control FTOC at day 4 was compared to a CD71 mAb-treated FTOC at day 12 (C). Cells were stained and analyzed as indicated for B.
culture Fig. 4A) .
Comparison of the developmental stage of the thymocytes in these particular samples showed that the CD71 mAbtreated culture contained more CD4-8-and CD4-V cells, but fewer CD4+8+ cells (Fig. 4B) . In addition, cells of the CD71 mAb-treated culture were all large in size, whereas the control culture also contained small cells (data not shown). This observation indicates that cells in CD71 mAb-treated cultures were generally less mature than cells in control cultures.
In a second experiment, under identical experimental conditions, the control culture at day 4 and the CD71 mAb-treated culture at day 12 contained comparable cell numbers (168000 and 181 000 cells per lobe, respectively; Fig. 4C ). Comparison of the developmental stages of these cultures, once more showed that more CD4-8-and CD4-8+ cells, but fewer CD4+8+ cells developed after CD71 mAb treatment and all cells were large in size (data not shown).
Together, these data suggest that (i) inhibition of differentiation is not just a consequence of inhibition of proliferation, and (ii) that terminal maturation of ap thymocytes requires higher intracellular iron levels than proliferation only.
Discussion
Iron is essential to proliferation of cells. Therefore, cells express the transferrin receptor (CD71) on the cell surface during cell cycle [14] . Recently, we have also shown that cycling immature thymocytes are characterized by CD71 expression [ 121. The importance of intracellular iron levels for maturational processes is much less known, however. In this study, we determined the importance of CD71 mediated iron uptake for both proliferation and maturation of thymocytes in FTOC.
Indeed, our data indicate that proliferation of thymocytes in FTOC is inhibited by CD71 mAb treatment. However, proliferation was only partially inhibited, and the number of cells still expanded tenfold from the start of the culture. Partial inhibition of proliferation was not caused by suboptimal mAb treatment, because all CD71 molecules were saturated with the CD71 mAb, even after 7 days of organ culture. Rather, this observation indicates that thymocytes can still internalize low levels of iron, likely, because the CD71 mAb ER-MP21 recognizes an epitope on CD71 different from the transferrin-binding site [16] . As a consequence, iron-loaded transferrin can still bind to the receptor and be internalized. However, for various cell types it was found that binding of the CD71 mAb severely decreases recycling of CD71 between the cell surface and the intracellular compartments and, consequently, renders cells iron deficient [ 16, 26, [28] [29] [30] . Likewise, thymocytes in FTOC became iron deficient, but, apparently, the low intracellular iron level could still support a low level of proliferation.
A major observation from our study is that the maturation of afi T cells, but not y6 T cells, in the FTOC was inhibited CD71 treatment, causing decreased intracellular iron levels, severely inhibits the major proliferation phase from the CD44-25+ CD4-8-3-to the CD4+8+3-cells, and completely abrogates the final maturation of CD4+8+3-cells into aPTcR-expressing cells. In contrast, proliferation and differentiation of the earliest thymic precursors into CD44-25+ CD4-8-3-cells is not affected by CD71 treatment.
by CD71 mAb treatment. Thymocytes expressing the CD3laPTcR complex at low or high level did not develop in the CD71 mAb-treated cultures. Similar to proliferation, the maturation of the cells was only partially inhibited: a small fraction of CD4-8-cells, present in day 14 fetal thymus, could still develop into CD4+8+3-cells. Consequently, it seems that in CD71 mAb-treated cultures, thymocytes can only develop to the transition point where CD3-cells start to mature into CD3Iow cells. Normally, cell division stops at this transition, cells enter the Go phase of the cell cycle and become small in size [6, 8, 311 . In addition, down-regulation of CD71 also marks the transition of CD3-to CD3*OW cells [12] . Our present findings suggest that maturation of immature aPTcR-thymocytes into aPTcR-expressing cells is critically dependent on the intracellular iron levels of the maturing thymocytes.
Despite the development of thymocytes up to the CD4+8+3-stage, our data suggest that CD71 treatment already affects thymocytes before the CD4+8+3-stage of T cell development. This suggestion was supported by the observation that all thymocyte subpopulations were severely reduced in cell number or even absent,with the exception of the CD4-8-3-cells. Additionally, we observed that in preliminary experiments using FTOC from day 16 embryos, proliferation and differentiation of cells were not inhibited by CD71 mAb treatment (data not shown). The most likely explanation of this preliminary finding is that day 16, in contrast to day 14, fetal thymocytes have passed the stage most sensitive to CD71 mAb treatment. Since day 16 fetal thymus, like day 14 fetal thymus, mainly contains CD4-8-thymocytes [12] , it seems likely that cells most sensitive for CD71 treatment belong to a subset within the CD4-8-3-thymocyte subpopulation.
Subsets of CD4-8-3-cells can be defined by expression of CD44 and CD25: CD44+25-cells develop via CD44-25+ into CD44-25-cells ( [9, 32] ; unpublished observations). Recently, the CD25+ CD4-8-3-stage of adult thymocyte differentiation was identified as a possible major branching point for the development of the three T cell lineages, i.e. the a6 T cells, the y6 T cells and the CD4-8-aP T cells [9, 331 . The development of the CD25+ CD4-8-3-cells is unaffected by CD71 mAb treatment. This is based on the observations, that (i) CD44-25+ cells develop in normal numbers in CD71 mAb treated cultures, and (ii) y6 T cells, developing from the CD25+ cells, are not affected by CD71 treatment.Together, these data suggest that the CD44-25+ CD4-8-3-cells or their immediate progeny, the CD44-25-CD4-8-3-cells, are probably most dependent on intracellular iron levels.
The development of y6 T cells, that also express CD71 ,was not affected by CD71 mAb treatment. This observation indicates that, in contrast to maturing ap T cells, y6 T cells apparently internalize sufficient amounts of iron to support their normal development. Two mechanisms can provide an explanation for this difference: (i) y6 T cells internalize more iron because, despite CD71 mAb treatment, cells still have a high CD71 recycling rate, or (ii) y6 T cells have lower iron requirements for differentiation than ap T cells.
In summary, our results indicate that iron deficiency, caused by CD71 mAb treatment, leads to an inhibition of ap T but not y6 T cell development. Our observations indicate that Iron deficiency, caused by malnutrition, is one of the most common health problems in third-world countries, and may lead to impaired cell-mediated immunity [34, 351. As our data indicate, this may be caused by the inhibition of afi T cell development within the thymus [36] .
